PPE family protein PPE18 (PPE18)

PPE family protein PPE18, commonly referred to as Mtb39A, is a 39-kDa cell-surface protein of Mycobacterium tuberculosis that serves as a potent virulence factor and a primary target for next-generation vaccines [9, 14]. It functions by interacting with the host's Toll-like receptor 2 (TLR2), which activates the p38 MAPK pathway and induces the expression of SOCS-3 [14]. This signaling cascade results in the production of immunosuppressive IL-10 and the inhibition of pro-inflammatory cytokines such as IL-12 and TNF-alpha, effectively shifting the host immune response toward a Th2-type environment that favors bacterial survival and persistence within macrophages [4, 14]. Additionally, PPE18 has been shown to inhibit MHC class II-mediated antigen presentation, further aiding the pathogen's evasion of the host's adaptive immune system [1 (Search 2)]. In therapeutic development, Mtb39A is most notable as a key component of the M72/AS01E subunit vaccine, where it is fused with the Mtb32A antigen [1, 2]. This vaccine is specifically designed to prevent the reactivation of latent tuberculosis by eliciting a robust Th1-type immune response, characterized by high levels of antigen-specific CD4+ T cells and interferon-gamma production [7, 8]. While Mtb39A itself is an immunosuppressive factor during natural infection, its use as a recombinant antigen in combination with powerful adjuvants has demonstrated significant efficacy in reducing the incidence of active pulmonary tuberculosis in clinical trials [2, 3]. Current research also explores the potential for direct inhibitors or host-directed therapies that could block the immunosuppressive interactions of PPE18 to enhance bacterial clearance [5 (Search 2)].

Other names

Mtb39A antigenRv1196MTB39AProline-proline-glutamic acid family protein 18

Stimulation of antigen-specific Th1-type immune response; Induction of CD4+ T-cell activation and interferon-gamma production; Indirect blockade of bacterial immune evasion